Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
ConditionUreteral Stent-Related Symptom
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBir Hospital
About this trial
A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics
Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy
Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases
Preoperative febrile Urinary Tract Infection (UTI)
Trial design
Design model
Parallel
Treatments tested in this trial
Tamsulosin Hydrochloride 0.4 mg
Drugplacement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
Solifenacin Succinate 5 mg
Drugplacement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
Mirabegron 25 mg
Drugplacement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
Treatment groups
189 Participants
are divided into 3 treatment groupsGroup A: Tamsulosin groupActive comparator 1 intervention
Group B: Solifenacin groupActive comparator 1 intervention
Group C: Mirabegron groupActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
alleviating Ureteral stent related symptoms
mitigating the ureteric stent related symptoms using structured questionnaire
Time frame
2 weeksSecondary outcomes
1
early removal of ureteral stent
early removal of stent due to stent migration, fever, urosepsis
Time frame
before 2 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Bir Hospital
Lead sponsor
Nepal Health Research Council
Collaborator
Source ClinicalTrials.gov